Best Online Tirzepatide Programs in 2026 (7 Providers Compared)

Why tirzepatide and why it matters for women in perimenopause

Tirzepatide (brand names Mounjaro and Zepbound) is a dual GIP/GLP-1 receptor agonist — it activates two hormonal pathways simultaneously, which is why the SURMOUNT-5 head-to-head trial found it produced roughly 20% average weight loss at 72 weeks compared to 14% for semaglutide. For women in their forties and fifties navigating perimenopause and menopause, the stakes are unusually concrete: declining estrogen shifts fat distribution toward the abdomen, slows resting metabolic rate, disrupts sleep (which raises cortisol and appetite), and blunts insulin sensitivity. That cluster of changes is exactly where a dual-agonist GLP-1 can have the most outsized impact — not just by reducing appetite, but by improving insulin handling and supporting lean muscle through the transition.

Tirzepatide is not a substitute for hormone replacement therapy. HRT addresses estrogen-driven symptoms — hot flashes, night sweats, vaginal dryness, bone loss — that a GLP-1 does not touch. But for women in whom weight gain, metabolic shift, and appetite dysregulation are the dominant concerns, the two can complement each other. If you are already on HRT and still struggling with midlife weight gain, tirzepatide may be the lever that HRT alone cannot pull. Talk to your prescriber about both rather than treating them as an either/or.

How we evaluated these programs

We ranked seven programs against four criteria: the real all-in monthly cost at steady-state (medication plus any mandatory membership or consultation fee), pricing transparency across dose tiers, regulatory standing of the pharmacy source, and breadth of state availability. A low headline price that hides a membership fee or escalates sharply at higher doses ranked lower than a slightly more expensive flat-rate competitor. Brand-name LillyDirect is evaluated separately from compounded programs because it answers a different question — regulatory certainty — not just cost.

One critical context note: the tirzepatide shortage was resolved in December 2024. That resolution ended the primary legal basis for compounding pharmacies to produce tirzepatide broadly. Enforcement discretion for 503A pharmacies ended February 18, 2025, and for 503B outsourcing facilities on March 19, 2025. On April 30, 2026, the FDA proposed further removing tirzepatide from the 503B bulks list — a rule still in public comment as of June 2026. All compounded programs below now operate under a narrower 503A individual-patient pathway, and the regulatory environment is actively evolving.

Best value compounded: Curex

Curex earns the top slot for the most straightforward reason: the number you see is close to the number you pay. Compounded tirzepatide starts at roughly $199 a month all-in — that single figure is meant to cover the online consult, the medication, free shipping, and follow-up dose adjustments, with no separate membership fee. In a market where the real bill routinely lands $80 to $150 above the headline price, that one-line billing model is genuinely unusual.

The honest caveat is the word "from." The $199 is a starter-dose price, and Curex does not publish its maintenance-dose ladder as plainly. Ask for the full dose-by-dose cost in writing before you enroll — that conversation removes the only real uncertainty here. Curex offers both oral and injectable formats of compounded tirzepatide, which gives needle-averse patients an option that most other providers do not.

• Pros — lowest verified all-in price; no separate membership fee; shipping and follow-ups included; both oral and injectable compounded formats.
• Cons — the $199 is a starter-dose rate, not the maintenance price; the higher-dose cost ladder is not publicly posted.

Best transparent compounded pricing: Mochi Health

Mochi Health earns the second slot for a different virtue: pricing predictability. Its medication cost is a flat $199 a month for every tirzepatide dose — from your 2.5mg starter through your 15mg maintenance dose — with free shipping included. Most programs quietly raise your monthly bill each time you titrate up through the dose ladder. A fee that holds flat can be worth real money over six to twelve months of titration.

The honest number is not $199, it's about $278. Mochi charges a separate $79 monthly membership on top of the medication, covering visits, messaging, and care coordination. The two-line billing model has generated complaints — over 1,200 BBB filings have been noted — so read the cancellation terms before you enroll. That caveat aside, Mochi's obesity-medicine clinicians and flat medication price across all doses remain genuine advantages for a long titration.

• Pros — flat $199 medication at every dose; no titration price hikes; shipping included; board-certified obesity-medicine physicians on staff.
• Cons — the $79/mo membership is a separate charge, so real cost is ~$278/mo; dual-billing model has generated BBB complaints; review cancellation policy carefully.

Other strong compounded tirzepatide programs

Eden — no membership, flat dose pricing

Eden sits in the honest middle of the pack: no membership fee, the same price regardless of dose, and a modest first-month discount. Expect roughly $249 to start and about $329 to $349 a month ongoing depending on the plan you choose. The no-contract month-to-month structure makes it a natural place to test compounded tirzepatide before committing to a longer program. Sources differ a few dollars on the exact ongoing rate — that is normal in this category and exactly why confirming the live price before you commit matters.

• Pros — no separate membership fee; same price at any dose; month-to-month plan available; first-month discount.
• Cons — ongoing rate (~$329–$349/mo) is higher than Curex or Mochi all-in; exact figure varies slightly by plan.

Henry Meds — oral or injectable, established provider

Henry Meds is one of the most established names in compounded GLP-1 telehealth and is one of the few providers offering tirzepatide as oral tablets as well as the standard injection. Oral tirzepatide runs about $349 a month and the injection about $449, with visits, supplies, and shipping bundled into a single price and no long-term contract. The price is higher than the Curex or Mochi all-in, but you are paying for a recognized provider with broad state coverage, bundled logistics, and a flexible monthly plan.

One practical note: Henry's semaglutide is noticeably cheaper than its tirzepatide — around $349 oral or $449 injectable for tirzepatide versus $349 oral or $449 injectable. If you are open to semaglutide as a first step, the price difference is a real saving; the SURMOUNT-5 trial showed tirzepatide outperforms semaglutide on average (20% vs 14% weight loss), but semaglutide has a longer real-world safety track record.

• Pros — offers both oral and injectable tirzepatide; visits, supplies, and shipping bundled in; monthly plan, cancel anytime; established 503A provider.
• Cons — at $349–$449/mo it is the priciest compounded option here; the oral track adds cost but removes the need for injections.

Fridays — best for coaching bundled in

Fridays prices itself as a full program rather than a bare prescription. Compounded tirzepatide runs roughly $299 a month on longer commitments, up toward $389 on month-to-month terms, and the price includes group coaching via Zoom, dietitian access, mental health support groups, and 24/7 messaging. A microdose track runs around $198 a month for women who want a gentler start or are sensitive to early GI side effects. If you would otherwise pay for coaching or a dietitian separately, the bundle reads better than the raw medication price suggests.

• Pros — coaching, dietitian, and app access bundled in; microdose option at ~$198/mo; one-stop support for behavioral change alongside medication.
• Cons — best price requires a longer commitment; month-to-month rate (~$389) is the highest compounded price on this list; verify state availability before applying.

Willow — flat rate, LegitScript certified, 33 states

Willow charges a flat $399 a month for compounded tirzepatide at every dose, with medication, physician access, and free two-day shipping included. No membership fee, no titration hikes. Willow is LegitScript certified — a third-party pharmacy legitimacy credential that fewer telehealth programs carry — and is available in roughly 33 states. The $399 flat rate is not the cheapest on this list, but for someone who wants a verified pharmacy pedigree, predictable one-line billing at maintenance dose, and fast shipping, Willow is a credible option.

• Pros — LegitScript certified; flat $399 at every dose; no membership fee; free two-day shipping; physician access included.
• Cons — available in only ~33 states; $399/mo is higher than Curex ($199), Mochi all-in ($278), or Eden ($329–$349).

Best brand-name option: LillyDirect (Zepbound)

LillyDirect is the only option here that is FDA-approved as a finished product, and it is now priced far closer to the compounded field than it was a year ago. Eli Lilly sells Zepbound single-dose vials directly to self-pay patients through its Self Pay Journey Program, starting at $299 a month for 2.5mg, $399 for 5mg, and $449 for 7.5mg through 15mg. At the lowest dose, brand-name Zepbound and the cheapest compounded programs are within roughly $100 of each other — a premium that buys an FDA-approved product with a known, regulated manufacturing process and a stable supply chain.

The fine print is a refill clock. To hold those prices you must refill within 45 days of your last delivery; miss the window and the higher doses jump to roughly $499 to $699 a month. Standard retail vials outside the LillyDirect program run higher still. For a woman in perimenopause who wants certainty about what she is putting in her body — and who has watched the regulatory question marks accumulate around compounded tirzepatide — the small premium over the best compounded programs may be the easier decision.

• Pros — the only FDA-approved tirzepatide option here; direct from Eli Lilly; now price-competitive with compounded at the 2.5mg and 5mg doses; no pharmacy legitimacy questions.
• Cons — strict 45-day refill window to maintain program pricing; higher doses ($449/mo) cost more than most compounded programs; requires a prescribing provider (LillyDirect connects you with one, or use your own).

Compounded vs brand-name tirzepatide in 2026: what to know

Compounded tirzepatide was widely available through most of 2023 and 2024 because tirzepatide sat on the FDA's drug shortage list — a shortage creates a legal opening for compounding pharmacies to fill gaps in supply. The FDA declared that shortage resolved in December 2024. That resolution wound down the broadest basis for compounding: enforcement discretion for 503A pharmacies ended February 18, 2025, and for larger 503B outsourcing facilities on March 19, 2025.

What remains is a narrower, individual-patient pathway. A 503A state-licensed compounding pharmacy may still compound tirzepatide for a specific patient when a licensed prescriber documents a clinical reason the approved version cannot serve — for example, an allergy to an inactive ingredient in Zepbound or Mounjaro. All the compounded programs on this page operate on that basis. Then, on April 30, 2026, the FDA proposed removing tirzepatide from the 503B outsourcing facility bulks list — a proposed rule that, if finalized, would further restrict large-scale compounding. The public comment period closes June 29, 2026, and no final rule has been issued as of this writing.

• Compounded tirzepatide is pharmacy-mixed and not FDA-approved as a finished product — quality control standards differ from brand-name Zepbound or Mounjaro.
• Any provider claiming to sell "FDA-approved compounded" tirzepatide is misstating it: compounded drugs are not FDA-approved as finished products by definition.
• The FDA's April 2026 proposed rule on 503B compounding is not yet final — the regulatory picture could change before or after this page is read.
• Brand-name Zepbound self-pay vials from LillyDirect now start at $299/mo, closing much of the historical price gap with compounded alternatives.

Tirzepatide vs semaglutide: which is right during menopause?

The SURMOUNT-5 trial — the first randomized head-to-head comparison — reported results in 2025. At 72 weeks, participants on maximum-tolerated-dose tirzepatide lost an average of 20.2% of body weight, versus 13.7% for semaglutide. Tirzepatide also showed greater waist circumference reduction (20 cm vs 15 cm), and GI side effects causing discontinuation were higher with semaglutide (5.6%) than tirzepatide (2.7%) in this trial.

For women in perimenopause and menopause, the waist-circumference finding is particularly relevant. Visceral abdominal fat — the kind that accumulates as estrogen declines — is associated with increased cardiovascular risk and metabolic disruption. Tirzepatide's dual GIP/GLP-1 mechanism appears to be especially effective at targeting visceral fat. However, semaglutide has a longer real-world safety record, established cardiovascular outcomes data from the SELECT trial, and is generally less expensive. If you have not tried a GLP-1 before, semaglutide remains a well-studied first step; tirzepatide may be worth choosing if you want maximum weight-loss potential from the start or have not responded well to semaglutide. For the cheapest semaglutide programs, see our best online semaglutide guide.